This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Seeking Alpha's Larry Smith Is Wrong Again About Northwest Bio.

Ms. Powers refers to Northwest Bio CEO Linda Powers, who owns approximately 40% of the company via some intertwined entities, including the company that manufactures DCVax. Smith believes Power's large ownership stake in Northwest Bio proves she has "skin in the game."

A more believable and less optimistic explanation: Powers can't convince institutional investors to buy the stock because they've checked out DCVax and found it lacking credibility. Retail investors, on the other hand, are more easily persuaded, thanks in part to articles promoting the company like those written by Smith.

Smith should know better given his past experience working on Wall Street. Hidden gems in the biotech sector, if they exist at all, don't remain hidden for long. Northwest Bio has been toiling in the dark for years -- and for good reason.

Adjust for last fall's 1-for-16 reverse stock split and Northwest Bio today is a 21-cent stock. The company's market value is a measly $85 million even with DCVax in a phase III study for GBM. Investors have looked at Northwest Bio and passed. Potential development and marketing partners -- Big Pharma companies eager and willing to write big checks for licensing promising new drugs -- have also looked over Northwest Bio and passed.

The Feuerstein-Ratain Rule hasn't been proven wrong yet and is unambiguous about Northwest Bio: DCVax will fail.

Smith believes otherwise. We'll see who's right eventually.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NWBO $1.92 -5.00%
AAPL $93.72 -0.32%
FB $100.89 -3.10%
GOOG $673.86 -1.40%
TSLA $153.74 -5.40%


Chart of I:DJI
DOW 15,899.39 -305.58 -1.89%
S&P 500 1,846.62 -33.43 -1.78%
NASDAQ 4,274.1250 -89.0190 -2.04%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs